Christopher Paradise

Senior Vice President, Research & Development RION Health Inc.

Chris Paradise serves as SVP of Research and Development at Rion, Inc. He holds a PhD in Molecular Pharmacology and Regenerative Medicine from the Mayo Clinic in Rochester, MN. Before joining Rion, Chris’s research efforts focused on engineering adult stem cells to create novel therapeutics for tissue regeneration. At Rion, Chris has been involved in the translation of Rion’s platelet-derived exosome therapeutic from its origins within the academia laboratories at the Mayo clinic to a clinical-stage Drug Product under evaluation in late-stage human clinical trials.

Seminars

Tuesday 22nd September 2026

Defining Potency Assays for Exosome Therapeutics to Link Mechanism of Action to Measurable Biological Activity & Better Understand Product CQAs

9:30 am

Establishing potency assays that reflect the proposed mechanism of action, including immunomodulation, angiogenesis or tissue repair
Moving beyond surrogate markers to functional readouts that capture biologically relevant exosome activity
Correlating in vitro potency with in vivo efficacy to support clinical translation and dose justification

Wednesday 23rd September 2026

Spotlighting the Clinical Application of Rion’s Platelet-Derived Exosome Therapeutic to Promote Tissue Repair & Improve Patient Outcomes

9:00 am

Honing Rion’s platelet-derived exosome technology and application in regenerative medicine
Reviewing outcomes from ongoing clinical programs in advanced wound care and musculoskeletal diseases
Presenting additional, future applications of exosome-based technologies as a therapeutic platform